A kind of medical cosmetic wound dressing and preparation method thereof

Abstract

The present invention belongs to the field of medical cosmetology technology, and particularly relates to a dressing for medical cosmetology wounds and a preparation method thereof. The above-mentioned dressing for medical cosmetology wounds is composed of the following raw materials in parts by weight: 0.1-0.5 parts of proanthocyanidin-isatoic anhydride, 1-3 parts of sodium hyaluronate, 0.5-1.2 parts of chitosan, 0.8-1.6 parts of silk fibroin, 1-1.4 parts of sodium alginate, 0.001-0.002 parts of phenoxyethanol, and 90-100 parts of pure water; the present invention prepares a high-performance dressing by scientifically proportioning proanthocyanidin-isatoic anhydride with sodium hyaluronate, chitosan, silk fibroin, sodium alginate, phenoxyethanol and pure water. The proanthocyanidin-isatoic anhydride prepared by the present invention has whitening and anti-inflammatory properties, and can promote the proliferation of fibroblasts within a certain concentration. The dressing of the present invention has a good effect in promoting wound healing after medical cosmetology.

Description

Technical Field

[0001] The present invention belongs to the technical field of medical cosmetology, and in particular relates to a dressing for medical cosmetology wounds and a preparation method thereof. Background Art

[0002] The current medical beauty industry is in a stage of rapid development, and the market size is constantly expanding. With the growing demand for beauty among consumers, the types of medical beauty projects are becoming more diverse, and the technology is constantly innovating. Non-surgical medical beauty projects are favored by more and more consumers due to their characteristics of less trauma and quick recovery. At the same time, surgical medical beauty projects are also constantly improving and improving to meet the needs of different consumers. However, both non-surgical and surgical medical beauty projects usually cause wounds of varying degrees.

[0003] According to the different treatment methods and the degree of trauma, medical cosmetic wounds can be roughly divided into the following categories: injection wounds, photoelectric wounds and surgical wounds. Medical dressings can promote wound healing and reduce the risk of pigmentation and scar formation. The application of medical dressings plays a vital role in the care and recovery process of some cosmetic projects. For example, medical dressings can relieve the discomfort of redness, swelling, stinging and other discomforts of wounds after medical cosmetic surgery and reduce inflammatory reactions. Medical dressings can also promote skin cell regeneration and repair, thereby promoting wound healing. Although medical dressings play an important role in wound healing after cosmetic projects, the dressings disclosed in the prior art still have many shortcomings, including the possibility of causing skin irritation and allergic reactions, weak anti-inflammatory function, and limited effect in improving pigmentation. These problems limit the wide application and treatment effect of medical dressings, and further technical improvements to medical dressings are urgently needed.

[0004] Proanthocyanidins provide strong support for improving skin quality and delaying skin aging. However, proanthocyanidins are easily affected by factors such as light, heat, and pH, and have poor stability. Therefore, the development of proanthocyanidin derivatives with strong efficacy, good stability, and non-toxicity will have broad prospects and application value. Summary of the invention

[0005] One of the purposes of the present invention is to provide a medical cosmetic wound dressing which has good anti-inflammatory and whitening effects and is suitable for wound repair in the field of medical cosmetics.

[0006] To achieve one of the purposes of the present invention, the technical solution adopted by the present invention is:

[0007] A medical cosmetic wound dressing is composed of the following raw materials in parts by weight: 0.1-0.5 parts of proanthocyanidin-isatoic anhydride, 1-3 parts of sodium hyaluronate, 0.5-1.2 parts of chitosan, 0.8-1.6 parts of silk fibroin, 1-1.4 parts of sodium alginate, 0.001-0.002 parts of phenoxyethanol, and 90-100 parts of pure water; wherein the structure of proanthocyanidin-isatoic anhydride is as follows:

[0008] .

[0009] Furthermore, the above-mentioned medical cosmetic wound dressing is composed of the following raw materials in parts by weight: 0.2 parts of proanthocyanidin-isatoic anhydride, 2 parts of sodium hyaluronate, 0.8 parts of chitosan, 1.2 parts of silk fibroin, 1.2 parts of sodium alginate, 0.001 parts of phenoxyethanol, and 90 parts of pure water.

[0010] Furthermore, the preparation process of the proanthocyanidin-isatoic anhydride comprises the following steps:

[0011] ;

[0012] (1) 4-nitroisatoic anhydride and (S)-3-aminobutyronitrile were reacted in pure water at 30-50°C for 2-4 hours, and then treated to obtain intermediate 1;

[0013] (2) intermediate 1 is reacted with carbon disulfide and an inorganic base in anhydrous ethanol at 80-90°C for 4-6 hours, and intermediate 2 is obtained after treatment;

[0014] (3) Proanthocyanidin, 4-formylphenylboronic acid and sodium bicarbonate were reacted in pure water for 4-6 hours, and intermediate 3 was obtained after treatment;

[0015] (4) Intermediate 2 and intermediate 3 are reacted in a 50% by volume aqueous ethanol solution for 8 to 16 hours, and then treated to obtain proanthocyanidin-isatoic anhydride.

[0016] Furthermore, in step (1), the molar ratio of 4-nitroisatoic anhydride to (S)-3-aminobutyronitrile is 1:1-1.2.

[0017] Furthermore, in step (2), the molar ratio of the intermediate 1 to carbon disulfide and the inorganic base is 1:1.2-1.5:1.5-1.8, and the inorganic base is one of potassium hydroxide and sodium hydroxide.

[0018] Furthermore, in step (3), the molar ratio of proanthocyanidins, 4-formylphenylboric acid and sodium bicarbonate is 1:1.8~2:0.01~0.02.

[0019] Furthermore, in step (4), the molar ratio of intermediate 3 to intermediate 2 is 1:2-2.5.

[0020] A second object of the present invention is to provide a method for preparing a medical cosmetic wound dressing.

[0021] To achieve the second purpose of the present invention, the technical solution adopted by the present invention is:

[0022] The preparation method of the above-mentioned medical cosmetic wound dressing comprises the following steps: adding sodium alginate, silk fibroin and proanthocyanidin-isatoic anhydride into pure water, stirring evenly, then adding chitosan, sodium hyaluronate and phenoxyethanol, and continuously stirring until completely dispersed to obtain a mixed system; keeping warm at 40-50°C for 40-60min, cooling to room temperature after the end of the keeping warm, and obtaining the medical cosmetic wound dressing.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] 1. The present invention scientifically mixes proanthocyanidin-isatoic anhydride with sodium hyaluronate, chitosan, silk fibroin, sodium alginate, phenoxyethanol and pure water to prepare a high-performance dressing. The proanthocyanidin-isatoic anhydride prepared by the present invention has whitening and anti-inflammatory properties, and promotes the proliferation of fibroblasts within a certain concentration. The dressing of the present invention has a good effect in promoting wound healing after medical cosmetology. The anhydride of 4-nitroisatoic anhydride and the amino group of (S)-3-aminobutyronitrile undergo nucleophilic substitution to generate an amide to obtain intermediate 1, the phenylamino group on intermediate 1 and the N on the amide group form a ring under the action of carbon disulfide to obtain intermediate 2, the ortho-phenolic hydroxyl group of proanthocyanidin and the boric acid of 4-formylphenylboronic acid undergo nucleophilic substitution to generate a pentavalent borate to obtain intermediate 3, and intermediate 2 and intermediate 3 undergo substitution reaction to obtain proanthocyanidin-isatoic anhydride.

[0025] 2. The preparation method of the present invention has been carefully optimized, and the process is simple and efficient. It is not only convenient for laboratory research, but also easier to scale up and apply in industrial production, ensuring the stability and consistency of product quality. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The synthetic route of proanthocyanidin-isatoic anhydride of the present invention is shown in FIG.

[0027] Figure 2 This is a schematic diagram of the effect of proanthocyanidin-isatoic anhydride on cell viability of the present invention;

[0028] Figure 3 This is a schematic diagram of the effect of the medical cosmetic wound dressing of the present invention on the IL-6 level in macrophages (RAW264.7 cells);

[0029] Figure 4 This is a schematic diagram of the effect of the medical cosmetic wound dressing of the present invention on the TNF-α level in macrophages (RAW264.7 cells);

[0030] Figure 5 The following are the toxicity test results of the dressings in the embodiments and comparative examples. DETAILED DESCRIPTION

[0031] Below, in conjunction with the accompanying drawings and specific embodiments, the present invention is further described. It should be noted that, under the premise of no conflict, the embodiments described below or the technical features can be arbitrarily combined to form new embodiments. The specific conditions not specified in the embodiments are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used, unless otherwise specified, are conventional products obtained through commercial channels. Example 1

[0032] A medical cosmetic wound dressing, comprising the following raw materials in percentage by weight: 0.2 parts of proanthocyanidin-isatoic anhydride, 2 parts of sodium hyaluronate, 0.8 parts of chitosan, 1.2 parts of silk fibroin, 1.2 parts of sodium alginate, 0.001 parts of phenoxyethanol, and 90 parts of pure water;

[0033] The preparation steps of the above-mentioned proanthocyanidin-isatoic anhydride are as follows:

[0034] (1) 4-Nitroisatoic anhydride (10 mmol) and (S)-3-aminobutyronitrile (10 mmol) were added to 100 mL of pure water, and then stirred at 40°C for 2.5 h. The reaction solution was filtered, and the filter cake was washed with cold ethanol, and then the filter cake was dried to obtain intermediate 1.

[0035] (2) Add intermediate 1 (10 mmol), carbon disulfide (12 mmol) and potassium hydroxide (15 mmol) to 50 mL of anhydrous ethanol and heat the reaction at 85 °C for 5 h. Then add the reaction solution into 0 °C water to quench the reaction. Use acetic acid to adjust the pH of the solution to 5. After the solid matter is obviously precipitated, filter it and wash the filter cake with pure water to obtain intermediate 2. 1 H NMR (C 12 H 10 N4O3S, 400MHz, DMSO-d6): δ 12.40 (s, 2H), 8.67 (s, 1H), 8.32-8.23 (m, 2H), 3.72 (m, 1H), 2.76-2.50 (m, 2H), 1.32 (d, 3H);

[0036] (3) Add proanthocyanidin (10 mmol) and sodium bicarbonate (0.1 mmol) to 100 mL of pure water, then add 4-formylphenylboronic acid (19 mmol), and stir at room temperature for 5 h. Then dialyze through a dialysis bag (molecular weight cutoff 500-1000 Da) to remove unreacted molecules, and concentrate and dry the solution in the dialysis bag to obtain intermediate 3. 1 H NMR (C 44 H 32 B2O 15 , 400MHz, DMSO-d6): δ 10.30 (s, 2H), 9.90 (s, 2H), 9.70 (s, 2H), 7.96-7.85 (m, 8H), 6.82-6.80 (m, 2H), 6.69-6.65 ( m, 4H), 5.95-5.89 (m, 4H), 5.10-5.04 (m, 3H), 4.80 (d, 1H), 4.58 (q, 1H), 2.77-2.54 (m, 2H);

[0037] (4) The obtained intermediate 2 (20 mmol) and intermediate 3 (10 mmol) were added to 100 mL of a mixed solution (ethanol and pure water 1:1), stirred at room temperature for 12 h, and then dialyzed using a dialysis bag (molecular weight cutoff 500-1000 Da) to remove unreacted molecules. The solution in the dialysis bag was concentrated and dried to obtain proanthocyanidin-isatoic anhydride.

[0038] Proanthocyanidin-isatoic anhydride 1 H NMR (C 68 H 48 B2N8O 19 S2, 400MHz, DMSO- d6 ): δ 12.40 (s, 2H), 10.30 (s, 2H), 9.70 (s, 2H), 8.65 (s, 2H), 8.32-8.23 (m, 4H), 7.68 (d, 4H), 7.33 (d, 4H), 7.06 (s, 2H), 6.93-6.80 (m, 3H), 6 [M+H] + m / z: 1367.27, ESI-MS (m / z): 1367.25.

[0039] The preparation process of the medical cosmetic wound dressing of this embodiment includes the following steps:

[0040] Add sodium alginate, silk fibroin and proanthocyanidin-isatoic anhydride into pure water, stir evenly, then add chitosan, sodium hyaluronate and phenoxyethanol, and continue stirring until completely dispersed to obtain a mixed system; keep warm at 40°C for 60 minutes, stir evenly after the end of the heat preservation, and cool to room temperature to obtain a medical cosmetic wound dressing. Example 2

[0041] A medical cosmetic wound dressing, comprising the following raw materials in percentage by weight: 0.5 parts of proanthocyanidin-isatoic anhydride, 3 parts of sodium hyaluronate, 1.2 parts of chitosan, 1.6 parts of silk fibroin, 1.4 parts of sodium alginate, 0.002 parts of phenoxyethanol, and 100 parts of pure water;

[0042] The preparation steps of the above-mentioned proanthocyanidin-isatoic anhydride are as follows:

[0043] (1) 4-Nitroisatoic anhydride (10 mmol) and (S)-3-aminobutyronitrile (12 mmol) were added to 100 mL of pure water, and then stirred at 30°C for 4 h. The reaction solution was filtered, and the filter cake was washed with cold ethanol, and then the filter cake was dried to obtain intermediate 1.

[0044] (2) Add intermediate 1 (10 mmol), carbon disulfide (15 mmol) and potassium hydroxide (18 mmol) to 50 mL of anhydrous ethanol and heat the reaction at 80 °C for 4 h. Then add the reaction solution into 0 °C water to quench the reaction. Use 1 M hydrochloric acid to adjust the pH of the solution to 3. After the solid matter is obviously precipitated, filter it and wash the filter cake with pure water to obtain intermediate 2. 1 The results of H NMR show that the structure of this example is consistent with that of Example 1;

[0045] (3) Add proanthocyanidin (10 mmol) and sodium bicarbonate (0.1 mmol) to 100 mL of pure water, then add 4-formylphenylboronic acid (20 mmol), and stir at room temperature for 4 h; dialyze through a dialysis bag (molecular weight cutoff 500-1000 Da) to remove unreacted molecules, and concentrate and dry the solution in the dialysis bag to obtain intermediate 3; 1 The results of H NMR show that the structure of this example is consistent with that of Example 1;

[0046] (4) The obtained intermediate 2 (25 mmol) and intermediate 3 (10 mmol) were added to 100 mL of a mixed solution (ethanol and pure water 1:1), stirred and reacted at room temperature for 8 h, and then dialyzed using a dialysis bag (molecular weight cutoff 500-1000 Da) to remove unreacted molecules. The solution in the dialysis bag was concentrated and dried to obtain proanthocyanidin-isatoic anhydride. 1 The results of H NMR and MS showed that the structure of this example was consistent with that of Example 1.

[0047] The preparation process of the medical cosmetic wound dressing of this embodiment includes the following steps:

[0048] Add sodium alginate, silk fibroin and proanthocyanidin-isatoic anhydride into pure water, stir evenly, then add chitosan, sodium hyaluronate and phenoxyethanol, and continue stirring until completely dispersed to obtain a mixed system; keep warm at 45°C for 50 minutes, stir evenly after the end of the heat preservation, and cool to room temperature to obtain a medical cosmetic wound dressing. Example 3

[0049] A medical cosmetic wound dressing, comprising the following raw materials in percentage by weight: 0.1 part of proanthocyanidin-isatoic anhydride, 1 part of sodium hyaluronate, 0.5 part of chitosan, 0.8 part of silk fibroin, 1 part of sodium alginate, 0.001 part of phenoxyethanol, and 90 parts of pure water;

[0050] The preparation steps of the above-mentioned proanthocyanidin-isatoic anhydride are as follows:

[0051] (1) 4-Nitroisatoic anhydride (10 mmol) and (S)-3-aminobutyronitrile (11 mmol) were added to 100 mL of pure water, and then stirred at 50°C for 4 h. The reaction solution was filtered, and the filter cake was washed with cold ethanol, and then the filter cake was dried to obtain intermediate 1.

[0052] (2) Add intermediate 1 (10 mmol), carbon disulfide (13 mmol) and sodium hydroxide (16 mmol) to 50 mL of anhydrous ethanol and heat at 90 °C for 5 h. Then add the reaction solution into 0 °C water to quench the reaction. Use acetic acid to adjust the pH of the solution to 5. After the solid matter is obviously precipitated, filter it and wash the filter cake with pure water to obtain intermediate 2. 1 The results of H NMR show that the structure of this example is consistent with that of Example 1;

[0053] (3) Add proanthocyanidin (10 mmol) and sodium bicarbonate (0.1 mmol) to 100 mL of pure water, then add 4-formylphenylboronic acid (18 mmol), and stir at room temperature for 5 h. Use a dialysis bag (molecular weight cutoff 500-1000 Da) to dialyze to remove unreacted molecules, and concentrate and dry the solution in the dialysis bag to obtain intermediate 3. 1 The results of H NMR show that the structure of this example is consistent with that of Example 1;

[0054] (4) The obtained intermediate 2 (22 mmol) and intermediate 3 (10 mmol) were added to 100 mL of a mixed solution (ethanol and pure water 1:1), stirred and reacted at room temperature for 8 h, and then dialyzed using a dialysis bag (molecular weight cutoff 500-1000 Da) to remove unreacted molecules. The solution in the dialysis bag was concentrated and dried to obtain proanthocyanidin-isatoic anhydride. 1 The results of H NMR and MS showed that the structure of this example was consistent with that of Example 1.

[0055] The preparation process of the medical cosmetic wound dressing of this embodiment includes the following steps:

[0056] Add sodium alginate, silk fibroin and proanthocyanidin-isatoic anhydride into pure water, stir evenly, then add chitosan, sodium hyaluronate and phenoxyethanol, and continue stirring until completely dispersed to obtain a mixed system; keep warm at 60°C for 40 minutes, stir evenly after the end of the heat preservation, and cool to room temperature to obtain a medical cosmetic wound dressing.

[0057] Comparative Example 1

[0058] A dressing for medical cosmetic wounds, which differs from Example 1 in that proanthocyanidin-isatoic anhydride is replaced with an equal amount of proanthocyanidin, and the rest is the same as Example 1.

[0059] Test Example 1

[0060] Effects of proanthocyanidin-isatoic anhydride on cell growth activity:

[0061] Take logarithmic phase fibroblasts, use a pipette to add 50 μL of cell suspension to each well, and inoculate 5000 fibroblasts per well into a 96-well plate; experimental group: different concentration gradients (7.5, 15, 30, 60 μM) of proanthocyanidin-isatoic anhydride solution (the proanthocyanidin-isatoic anhydride prepared in Example 1 was dissolved in cell culture medium to prepare a 60 μM proanthocyanidin-isatoic anhydride mother solution, and then the proanthocyanidin-isatoic anhydride mother solution was diluted with DMEM culture medium to obtain proanthocyanidin-isatoic anhydride solutions of required different concentrations) and proanthocyanidin solution (the solution preparation method was consistent with the preparation method of proanthocyanidin-isatoic anhydride solution), negative control group: no proanthocyanidin-isatoic anhydride and proanthocyanidin were added to each well. Three replicate wells were set for each concentration of proanthocyanidin-isatoic anhydride and proanthocyanidin, and cultured in a 37°C, 5% CO2 incubator; after 48 hours of incubation, 30 μL of 5 mg / mL MTT solution was added, and the reaction was terminated after another 4 hours of incubation; the absorbance (OD value) of each well was measured at 570 nm using an ELISA reader to calculate cell viability. Cell viability (%) = OD value of the experimental group / OD value of the negative control group × 100%, the specific results are as follows Figure 2 shown.

[0062] Depend on Figure 2The results showed that the addition of proanthocyanidin-isatoic anhydride could effectively promote the growth of fibroblasts, and the effect was better than that of proanthocyanidin.

[0063] Test Example 2

[0064] Proanthocyanidin-isatoic anhydride tyrosinase inhibitory activity test:

[0065] B16 melanoma cells in the logarithmic growth phase were collected and the concentration was 1×10 4 Cells were inoculated into 96-well plates at 100 μL / well and cultured in a 37°C incubator using DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin for 24 h; the cells were washed with 100 μL PBS (pH = 6.8), and 100 μL PBS containing 1% TritonX-100 was added to each well, followed by uniform mixing at 37°C for 30 min; 50 μL of the supernatant was transferred to the wells of a new plate, and 50 μL of proanthocyanidin-isatoic anhydride (0.1 mg / mL, solvent is PBS) and proanthocyanidin (0.1 mg / mL, solvent is PBS) provided in Example 1 were added to the experimental group, and 50 μL PBS was added to the blank control group. 50 μL of 5 mM levodopa solution was added to the proanthocyanidin-isatoic anhydride group and the proanthocyanidin group, respectively, and the absorbance (475 nm) was measured using a plate reader as the initial amount of dopa-chrome; then, the mixture was stirred at 37°C for 35 min, and the absorbance (475 nm) was measured again as the final absorbance of the reaction system, and the amount of dopa-chrome after storage was measured to determine the level of inhibition of tyrosinase activity. Based on the measured values ​​obtained, the inhibition rates of tyrosinase in the proanthocyanidin-isatoic anhydride group and the proanthocyanidin group were calculated when the tyrosinase activity of the blank control group was set to 1, as shown in Table 1.

[0066]

[0067] As can be seen from Table 1, the inhibition rate of tyrosinase by proanthocyanidin-isatoic anhydride of the present invention is higher than that of proanthocyanidin in the comparative example 1 group, which indicates that the proanthocyanidin-isatoic anhydride of the present invention has a better whitening effect than proanthocyanidin.

[0068] Test Example 3

[0069] Anti-inflammatory performance test of the medical cosmetic wound dressing of the present invention:

[0070] Mouse macrophages (RAW264.7 cells) were cultured in sterile DMEM high glucose medium containing DMEM + 10% fetal bovine serum at 5% CO. 2、 RAW264.7 cells were cultured in a 37°C cell culture incubator for 24 h;

[0071] Take RAW264.7 cells in logarithmic growth period and adjust the volume to 2×10 5 1 mL / well of cell suspension was inoculated into a 6-well plate and incubated at 5% CO 2、 Cultured in a cell culture incubator at 37°C for 24 hours, and replaced with fresh culture medium: blank control group: only culture medium was added; Example 1-3 groups and comparative example 1 group: fresh culture medium was replaced in the wells, containing 1 μg / mL LPS and 20 μg / mL corresponding dressings, and 3 replicates were set in each group; culture was continued for 24 hours, the culture medium in the wells was collected, centrifuged at 4000 r / min for 15 minutes, and the supernatant was taken. According to the operating steps in the kit instructions, the ELISA method was used to detect the levels of TNF-α and IL-6 in the culture medium. The specific results are shown in the figure. Figure 3 , Figure 4 shown.

[0072] Depend on Figure 3 , Figure 4 It can be seen that the medical cosmetic wound dressing of the present invention can reduce the LPS-induced TNF-α and IL-6 secretion. The results show that the medical cosmetic wound dressing of the present invention can inhibit LPS-induced RAW264.7 cell inflammation.

[0073] Test Example 4

[0074] Wound healing test and preliminary toxicity test of the medical cosmetic wound dressing of the present invention:

[0075] A total of 50 SD rats with similar growth status (such as body weight and fur status) were selected and randomly divided into 5 groups. The rats were anesthetized with Zota (dose of 50 mg / kg) by intraperitoneal injection, the hair on the back was removed with a depilatory agent, and a full-thickness skin injury model with an area of ​​about 2 cm×2 cm was made on the back of the rats by paraffin droplets;

[0076] The dressings of Examples 1 to 3 and Comparative Example 1 were evenly applied to the wound sites of each group with a coating thickness of 2 mm, and then bandaged with sterile gauze. The dressings were changed every 2 days for 14 consecutive days. The healing areas of the wounds on the 7th and 14th days were counted. The results are shown in Table 2.

[0077]

[0078] It can be seen from Table 2 that, compared with Examples 1 to 3, the wound healing performance of the dressing of Comparative Example 1 is significantly reduced, which indicates that the dressing of the present invention has better performance in promoting wound healing.

[0079] At the same time, in order to preliminarily evaluate the toxic effects of the dressings of the present invention, the hearts, kidneys, livers, spleens and lungs of rats that used the dressings for 14 consecutive days were isolated, fixed with formalin, embedded in paraffin, sliced, and stained with hematoxylin and eosin (H&E). Figure 5 shown.

[0080] Depend on Figure 5 It can be seen that the tissue sections of Examples 1-3 are similar to the tissue sections of Comparative Example 1, and it can be seen that Examples 1 to 3 did not cause significant pathological changes in the heart, liver, spleen, lungs and kidneys of rats, which shows that the dressing of the present invention has good safety and no obvious toxicity.

[0081] The above-mentioned embodiments are only preferred embodiments of the present invention and cannot be used to limit the scope of protection of the present invention. Any non-substantial changes and substitutions made by technicians in this field on the basis of the present invention shall fall within the scope of protection required by the present invention.

Claims

1. A medical cosmetic wound dressing, characterized in that: The composition is composed of the following raw materials in parts by weight: 0.1-0.5 parts of proanthocyanidin-isatoic anhydride, 1-3 parts of sodium hyaluronate, 0.5-1.2 parts of chitosan, 0.8-1.6 parts of silk fibroin, 1-1.4 parts of sodium alginate, 0.001-0.002 parts of phenoxyethanol, and 90-100 parts of pure water; wherein the structure of proanthocyanidin-isatoic anhydride is as follows: 。 2. The medical cosmetic wound dressing according to claim 1, characterized in that: The invention is composed of the following raw materials in parts by weight: 0.2 parts of proanthocyanidin-isatoic anhydride, 2 parts of sodium hyaluronate, 0.8 parts of chitosan, 1.2 parts of silk fibroin, 1.2 parts of sodium alginate, 0.001 parts of phenoxyethanol and 90 parts of pure water.

3. The medical cosmetic wound dressing according to claim 1, characterized in that: The preparation process of the proanthocyanidin-isatoic anhydride comprises the following steps: (1) 4-nitroisatoic anhydride and (S)-3-aminobutyronitrile were reacted in pure water at 30-50°C for 2-4h, and then treated to obtain intermediate 1; (2) intermediate 1 is reacted with carbon disulfide and an inorganic base in anhydrous ethanol at 80-90°C for 4-6 hours, and intermediate 2 is obtained after treatment; (3) Proanthocyanidin, 4-formylphenylboronic acid and sodium bicarbonate were reacted in pure water for 4-6 hours, and intermediate 3 was obtained after treatment; (4) intermediate 2 and intermediate 3 are reacted in a 50% by volume ethanol aqueous solution for 8 to 16 hours, and then treated to obtain proanthocyanidin-isatoic anhydride; The structural formula of the intermediate 1 is: ; The structural formula of the intermediate 2 is: ; The structural formula of the intermediate 3 is: .

4. The medical cosmetic wound dressing according to claim 3, characterized in that: The molar ratio of 4-nitroisatoic anhydride to (S)-3-aminobutyronitrile in step (1) is 1:1-1.

2.

5. The medical cosmetic wound dressing according to claim 3, characterized in that: In step (2), the molar ratio of the intermediate 1 to carbon disulfide and the inorganic base is 1:1.2-1.5:1.5-1.8, and the inorganic base is one of potassium hydroxide and sodium hydroxide.

6. The medical cosmetic wound dressing according to claim 3, characterized in that: The molar ratio of proanthocyanidins, 4-formylphenylboric acid and sodium bicarbonate in step (3) is 1:1.8~2:0.01~0.

02.

7. The medical cosmetic wound dressing according to claim 3, characterized in that: In step (4), the molar ratio of intermediate 3 to intermediate 2 is 1:2-2.

5.

8. The method for preparing the medical cosmetic wound dressing according to any one of claims 1 to 7, characterized in that: The method comprises the following steps: adding sodium alginate, silk fibroin and proanthocyanidin-isatoic anhydride into pure water, stirring evenly, then adding chitosan, sodium hyaluronate and phenoxyethanol, and continuously stirring until completely dispersed to obtain a mixed system; keeping the mixture at 40-50°C for 40-60 minutes, cooling to room temperature after the heat preservation, and obtaining a medical cosmetic wound dressing.

Images